Our study provides support for the argument that CNS involvement should not be deemed an absolute contraindication to CAR-T cell therapy. With the implementation of suitable management and treatment strategies, CAR-T therapy can proficiently target tumor cells within the CNS. This treatment option may be particularly beneficial for relapsed or refractory patients, as well as those with central nervous system involvement who have shown limited response to conventional therapies. Additionally, CAR-T cell therapy may serve as a valuable bridge to allogeneic hematopoietic stem cell transplantation (allo-HSCT) in these patients.
Keyphrases
- cell therapy
- end stage renal disease
- acute lymphoblastic leukemia
- allogeneic hematopoietic stem cell transplantation
- acute myeloid leukemia
- stem cells
- newly diagnosed
- ejection fraction
- chronic kidney disease
- mesenchymal stem cells
- bone marrow
- healthcare
- primary care
- prognostic factors
- diffuse large b cell lymphoma
- blood brain barrier
- hodgkin lymphoma
- cerebrospinal fluid
- high dose
- replacement therapy
- combination therapy